**Professor Peter Gibbs -** *Research and Education Lead for GastroIntestinal Cancer, VCCC Alliance; Laboratory Head and Divisional Lead, WEHI; Medical Oncologist, Western Health*

**Registry enabled translational research**

Multi-site colorectal cancer data collection commenced in 2000, with a growing number of participating sites and research directions. I will focus on how registry data efforts led from WEHI, is studies of prognostic (e.g., ctDNA) and predictive markers (organoid sensitivity), enabling us to better understand clinical practice and defining opportunities for improvement.

**Professor John Mariadason -** *Head, Division of Gastrointestinal Cancers, ONJCRI*

**Colorectal cancer research underway at Austin Health and the ONJCRI**

Prof Mariadason will provide an overview of colorectal cancer research activities underway at Austin Health and the ONJCRI, highlighting our strengths in genetic mouse models of the disease, modelling colorectal cancer metastasis *in vivo*, molecular and pathological subclassification of CRCs, and the use of CRC cell line models for assessing therapy response and biomarker discovery.

**Dr Fiona Chionh -** *Postdoctoral Research Fellow, ONJCRI*

**Colorectal cancer research underway at Austin Health and the ONJCRI**

Dr Chionh will provide an overview of research being undertaken by clinician-scientists in a successful translational colorectal cancer research program at the ONJCRI, highlighting opportunities for collaborations with scientists, clinician-scientists and clinician researchers.

**Associate Professor Ian Hayes -** *Head of Colorectal Surgery Unit, RMH***;** *Head of Emergency General surgery Unit RMH***;** *Clinical Associate Professor, Dept of Surgery, The University of Melbourne*

**Clinical outcomes research projects in colorectal cancer from RMH Colorectal Surgery Unit**

Statewide administrative data and data linkage projects in colorectal cancer surgery. Biogrid clinical database projects in colorectal cancer surgery.

**Professor Rob Ramsay -** *Co-Head of Gastrointestinal Cancer Program and Head of the Differentiation and Transcription Laboratory at the Peter MacCallum Cancer Centre and the Peter MacCallum Department of Oncology; Honorary Professor, Department of Clinical Pathology, The University of Melbourne.*

**Responding to real world gaps in managing colorectal cancer**

Identifying the gaps in the treatment of patients with colorectal cancer is central to improving survival and quality of life. There is an additional potential is realising genuine health economics benefits. In this presentation points of intervention along the patient management pathway will be noted and research activities that address these will be highlighted. These will include how aspects of laparoscopic and open surgery that might be optimised, the role of implementing enhanced recovery after surgery (ERAS), getting the best predictive models for choosing the most active chemotherapy drugs and modes of delivery of radiotherapy and finally addressing the differences between the predominant sites of metastasis will be summarised.

**Associate Professor Sue-Anne McLachlan -** *Medical Oncologist, Director of Oncology and Cancer Services, SVHM*

**Fear of Cancer Recurrence sub-studies of the DYNAMIC trials**

This study will provide the first informationabout **Fear of Cancer Recurrence** when using molecular information to determine adjuvant chemotherapy for patients with early stage colo-rectal cancer**.** Fear of Cancer Recurrence (FCR) is defined as “*fear, worry, or concern relating to the possibility that cancer will come back or progress*” and is one of the most common unmet needs for help amongst cancer survivors. Little is known about FCR in relation to personalised medicine. Ultimately having information like this will inform the design and tailoring of interventions to help cancer survivors cope better with FCR, and improve their quality of life.

**Associate Professor Justin Yeung -** *Consultant Colorectal Surgeon, Western Health*

**Tailoring colorectal cancer treatment – How can we do better?**

Summary of novel methods of improving and tailoring colorectal cancer treatment based on patient “big data”.

**Dr Koen Degeling –** *Research Fellow, Cancer Health Services Research, Centre for Health Policy and Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne*

**Data-driven simulation modelling to inform (early) health technology assessment**

This presentation will focus on the use of real-world data from clinical registries to inform (early) health technology assessment through economic simulation modelling. The presented research studies utilise the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD) and Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registries to estimate 1) the health economic potential of biomarkers to inform adjuvant chemotherapy for stage II colorectal cancer, 2) the cost-effectiveness of ctDNA specifically to inform adjuvant chemotherapy for stage II colorectal cancer, and 3) the number of patients eligible for different treatment at different disease stages and treatment lines.